Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting

Rebecca Landy, Mark Schiffman, Peter D. Sasieni, Li C. Cheung, Hormuzd A. Katki, Greg Rydzak, Nicolas Wentzensen, Nancy E. Poitras, Thomas Lorey, Walter K. Kinney, Philip E. Castle

Research output: Contribution to journalArticle

Abstract

US guidelines recommend that most women older than 65 years cease cervical screening after two consecutive negative cotests (concurrent HPV and cytology tests) in the previous 10 years, with one in the last 5 years. However, this recommendation was based on expert opinion and modeling rather than empirical data on cancer risk. We therefore estimated the 5-year risks of cervical precancer (cervical intraepithelial neoplasia grade 3 or adenocarcinoma in situ [CIN3]) after one, two and three negative cotests among 346,760 women aged 55–64 years undergoing routine cotesting at Kaiser Permanente Northern California (2003–2015). Women with a history of excisional treatment or CIN2+ were excluded. No woman with one or more negative cotests was diagnosed with cancer during follow-up. Five-year risks of CIN3 after one, two, and three consecutive negative cotests were 0.034% (95% CI: 0.023%–0.046%), 0.041% (95% CI: 0.007%–0.076%) and 0.016% (95% CI: 0.000%–0.052%), respectively (p trend < 0.001). These risks did not appreciably differ by a positive cotest result prior to the one, two or three negative cotest(s). Since CIN3 risks after one or more negative cotests were significantly below a proposed 0.12% CIN3+ risk threshold for a 5-year screening interval, a longer screening interval in these women is justified. However, the choice of how many negative cotests provide sufficient safety against invasive cancer over a woman's remaining life represents a value judgment based on the harms versus benefits of continued screening. Ideally, this guideline should be informed by longer-term follow-up given that exiting is a long-term decision.

Original languageEnglish (US)
JournalInternational Journal of Cancer
DOIs
StatePublished - Jan 1 2019

Fingerprint

Cell Biology
Guidelines
Neoplasms
Cervical Intraepithelial Neoplasia
Expert Testimony
Safety

Keywords

  • cervical cancer
  • cervical screening
  • cotesting
  • exiting
  • guidelines
  • HPV

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting. / Landy, Rebecca; Schiffman, Mark; Sasieni, Peter D.; Cheung, Li C.; Katki, Hormuzd A.; Rydzak, Greg; Wentzensen, Nicolas; Poitras, Nancy E.; Lorey, Thomas; Kinney, Walter K.; Castle, Philip E.

In: International Journal of Cancer, 01.01.2019.

Research output: Contribution to journalArticle

Landy, R, Schiffman, M, Sasieni, PD, Cheung, LC, Katki, HA, Rydzak, G, Wentzensen, N, Poitras, NE, Lorey, T, Kinney, WK & Castle, PE 2019, 'Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting', International Journal of Cancer. https://doi.org/10.1002/ijc.32268
Landy, Rebecca ; Schiffman, Mark ; Sasieni, Peter D. ; Cheung, Li C. ; Katki, Hormuzd A. ; Rydzak, Greg ; Wentzensen, Nicolas ; Poitras, Nancy E. ; Lorey, Thomas ; Kinney, Walter K. ; Castle, Philip E. / Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting. In: International Journal of Cancer. 2019.
@article{c87a0cd2c0a94f2f94410a45a56151bc,
title = "Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting",
abstract = "US guidelines recommend that most women older than 65 years cease cervical screening after two consecutive negative cotests (concurrent HPV and cytology tests) in the previous 10 years, with one in the last 5 years. However, this recommendation was based on expert opinion and modeling rather than empirical data on cancer risk. We therefore estimated the 5-year risks of cervical precancer (cervical intraepithelial neoplasia grade 3 or adenocarcinoma in situ [CIN3]) after one, two and three negative cotests among 346,760 women aged 55–64 years undergoing routine cotesting at Kaiser Permanente Northern California (2003–2015). Women with a history of excisional treatment or CIN2+ were excluded. No woman with one or more negative cotests was diagnosed with cancer during follow-up. Five-year risks of CIN3 after one, two, and three consecutive negative cotests were 0.034{\%} (95{\%} CI: 0.023{\%}–0.046{\%}), 0.041{\%} (95{\%} CI: 0.007{\%}–0.076{\%}) and 0.016{\%} (95{\%} CI: 0.000{\%}–0.052{\%}), respectively (p trend < 0.001). These risks did not appreciably differ by a positive cotest result prior to the one, two or three negative cotest(s). Since CIN3 risks after one or more negative cotests were significantly below a proposed 0.12{\%} CIN3+ risk threshold for a 5-year screening interval, a longer screening interval in these women is justified. However, the choice of how many negative cotests provide sufficient safety against invasive cancer over a woman's remaining life represents a value judgment based on the harms versus benefits of continued screening. Ideally, this guideline should be informed by longer-term follow-up given that exiting is a long-term decision.",
keywords = "cervical cancer, cervical screening, cotesting, exiting, guidelines, HPV",
author = "Rebecca Landy and Mark Schiffman and Sasieni, {Peter D.} and Cheung, {Li C.} and Katki, {Hormuzd A.} and Greg Rydzak and Nicolas Wentzensen and Poitras, {Nancy E.} and Thomas Lorey and Kinney, {Walter K.} and Castle, {Philip E.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/ijc.32268",
language = "English (US)",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting

AU - Landy, Rebecca

AU - Schiffman, Mark

AU - Sasieni, Peter D.

AU - Cheung, Li C.

AU - Katki, Hormuzd A.

AU - Rydzak, Greg

AU - Wentzensen, Nicolas

AU - Poitras, Nancy E.

AU - Lorey, Thomas

AU - Kinney, Walter K.

AU - Castle, Philip E.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - US guidelines recommend that most women older than 65 years cease cervical screening after two consecutive negative cotests (concurrent HPV and cytology tests) in the previous 10 years, with one in the last 5 years. However, this recommendation was based on expert opinion and modeling rather than empirical data on cancer risk. We therefore estimated the 5-year risks of cervical precancer (cervical intraepithelial neoplasia grade 3 or adenocarcinoma in situ [CIN3]) after one, two and three negative cotests among 346,760 women aged 55–64 years undergoing routine cotesting at Kaiser Permanente Northern California (2003–2015). Women with a history of excisional treatment or CIN2+ were excluded. No woman with one or more negative cotests was diagnosed with cancer during follow-up. Five-year risks of CIN3 after one, two, and three consecutive negative cotests were 0.034% (95% CI: 0.023%–0.046%), 0.041% (95% CI: 0.007%–0.076%) and 0.016% (95% CI: 0.000%–0.052%), respectively (p trend < 0.001). These risks did not appreciably differ by a positive cotest result prior to the one, two or three negative cotest(s). Since CIN3 risks after one or more negative cotests were significantly below a proposed 0.12% CIN3+ risk threshold for a 5-year screening interval, a longer screening interval in these women is justified. However, the choice of how many negative cotests provide sufficient safety against invasive cancer over a woman's remaining life represents a value judgment based on the harms versus benefits of continued screening. Ideally, this guideline should be informed by longer-term follow-up given that exiting is a long-term decision.

AB - US guidelines recommend that most women older than 65 years cease cervical screening after two consecutive negative cotests (concurrent HPV and cytology tests) in the previous 10 years, with one in the last 5 years. However, this recommendation was based on expert opinion and modeling rather than empirical data on cancer risk. We therefore estimated the 5-year risks of cervical precancer (cervical intraepithelial neoplasia grade 3 or adenocarcinoma in situ [CIN3]) after one, two and three negative cotests among 346,760 women aged 55–64 years undergoing routine cotesting at Kaiser Permanente Northern California (2003–2015). Women with a history of excisional treatment or CIN2+ were excluded. No woman with one or more negative cotests was diagnosed with cancer during follow-up. Five-year risks of CIN3 after one, two, and three consecutive negative cotests were 0.034% (95% CI: 0.023%–0.046%), 0.041% (95% CI: 0.007%–0.076%) and 0.016% (95% CI: 0.000%–0.052%), respectively (p trend < 0.001). These risks did not appreciably differ by a positive cotest result prior to the one, two or three negative cotest(s). Since CIN3 risks after one or more negative cotests were significantly below a proposed 0.12% CIN3+ risk threshold for a 5-year screening interval, a longer screening interval in these women is justified. However, the choice of how many negative cotests provide sufficient safety against invasive cancer over a woman's remaining life represents a value judgment based on the harms versus benefits of continued screening. Ideally, this guideline should be informed by longer-term follow-up given that exiting is a long-term decision.

KW - cervical cancer

KW - cervical screening

KW - cotesting

KW - exiting

KW - guidelines

KW - HPV

UR - http://www.scopus.com/inward/record.url?scp=85064002931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064002931&partnerID=8YFLogxK

U2 - 10.1002/ijc.32268

DO - 10.1002/ijc.32268

M3 - Article

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

ER -